Medication info
Omeprazole Magnesium Trihydrate 20 mg (Omeprazole Magnesium Trihydrate)

Omeprazole Magnesium Trihydrate 20 mg (Omeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
Samik Pharmaceutical Co., Ltd.
Appearance
Pale pink round film-coated tablet
Packaging
28 tablets (14 tablets/Alu-Alu X 2), 28 tablets (7 tablets/Alu-Alu X 4)
Approval status
Active

MFDS item code 201600875 · Approved 2016.02.16 · Insurance code 644003710

Summary

Main use
Treatment of gastrointestinal disorders (reflux·ulcers·symptoms due to anti-inflammatory drugs, etc.), eradication, Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This drug should be swallowed with a liquid such as water and should not be chewed or crushed. Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Long-term maintenance treatment to prevent recurrence in patients with esophagitis: 20 mg once daily. Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Once symptoms have resolved, subsequent recurrent symptoms may be controlled by administering 20 mg once daily. In adults, 20 mg once daily may be administered as needed. For patients at high risk of developing gastric or duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs, as-needed administration is not recommended for controlling recurrent symptoms. Antibiotic combination therapy for eradication of Helicobacter pylori: Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical trials exceeding 4 weeks have not been conducted. Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. Thereafter, the dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into two doses. Maintenance treatment following intravenous induction to prevent rebleeding from gastric or duodenal ulcers: Administer 40 mg once daily for 4 weeks after intravenous induction to prevent rebleeding from gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. Elderly: No dose adjustment is necessary.
Children's dosage
Adolescents 12 years and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Adolescents 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Adolescents 12 years and older — Once symptoms have resolved, subsequent recurrent symptoms may be controlled by administering 20 mg once daily. Children under 12 years — There is no experience with administration of this drug to children under 12 years.

Ingredients

Manufacturer
Samik Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of gastrointestinal disorders (reflux·ulcers·symptoms due to anti-inflammatory drugs, etc.), eradication, Zollinger-Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive gastroesophageal reflux disease
  • esophagitis
  • Helicobacter pylori positive duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the treatment of erosive gastroesophageal reflux disease (GERD) and for maintenance therapy to prevent long-term recurrence. It is also effective for symptom relief in gastroesophageal reflux disease without esophagitis. It is used in combination with antibiotics for the treatment of Helicobacter pylori positive duodenal ulcers and peptic ulcers and to prevent recurrence. It helps in treating upper gastrointestinal symptoms associated with NSAIDs (both non-selective and selective COX-2), as well as in the treatment and prevention of gastric ulcers. It is also applied in the treatment of Zollinger-Ellison syndrome and maintenance therapy after preventing rebleeding from gastric or duodenal ulcers. Overall, it improves the treatment and symptom relief of gastrointestinal diseases.

Dosage and Administration

Adult dosage

This drug should be swallowed with a liquid such as water and should not be chewed or crushed. Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Long-term maintenance treatment to prevent recurrence in patients with esophagitis: 20 mg once daily. Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Once symptoms have resolved, subsequent recurrent symptoms may be controlled by administering 20 mg once daily. In adults, 20 mg once daily may be administered as needed. For patients at high risk of developing gastric or duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs, as-needed administration is not recommended for controlling recurrent symptoms. Antibiotic combination therapy for eradication of Helicobacter pylori: Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical trials exceeding 4 weeks have not been conducted. Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. Thereafter, the dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into two doses. Maintenance treatment following intravenous induction to prevent rebleeding from gastric or duodenal ulcers: Administer 40 mg once daily for 4 weeks after intravenous induction to prevent rebleeding from gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. Elderly: No dose adjustment is necessary.

Children's dosage

Adolescents 12 years and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Adolescents 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Adolescents 12 years and older — Once symptoms have resolved, subsequent recurrent symptoms may be controlled by administering 20 mg once daily. Children under 12 years — There is no experience with administration of this drug to children under 12 years.

Precautions

This medication should not be used in patients with specific allergic reactions or those taking certain antibiotics or medications. It is advisable for breastfeeding women and patients with myocardial infarction to avoid this medication. This medication contains yellow dye, so caution is required for those allergic to this ingredient. Various adverse reactions may occur during use, so if symptoms arise, immediate consultation with healthcare professionals is necessary. It is important to monitor health status regularly through examinations during long-term use. It may interact with other medications, so it is crucial to inform healthcare professionals of any other medications being taken. Caution is advised during pregnancy, and use should be avoided while breastfeeding. In case of overdose, immediate medical attention is necessary as no specific antidote exists. Store in a place out of reach of children, and do not transfer to other containers.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, dysgeusia, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, pruritus, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized pustular psoriasis, drug reactions related to eosinophilia and systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reactions, back pain, chest pain, retrosternal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, flushing, hypertension, tachycardia, thyroid gland enlargement, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal motility disorders, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased plasma gastrin, glossopathy, tongue edema, ulcerative stomatitis, ear pain, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, convulsions, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, anorexia, apathy, increased appetite, confusion, worsening depression, muscular hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremor, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, dysosmia, ageusia, hypogeusia, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic polyp, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container to protect it from air and moisture, preferably at room temperature between 1°C and 30°C. This will maintain the drug's efficacy and safety.

Appearance and packaging

Appearance

Pale pink round film-coated tablet

Package unit

28 tablets (14 tablets/Alu-Alu X 2), 28 tablets (7 tablets/Alu-Alu X 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.